<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Tuberculostatics, antileprotics</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8sMEGsKGkAAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAEBUlEQVRIx62V22tdRRTGf7Nn73P2ybntnNOe3NqkPTGgLTVUUZF6QatSLOKTPgqCIqLgQ0H/A1sQQbBYCBb1QfAxiC8tSO1FqHkwJVKtjdTGNraUmObsc9nXmfGh7cGYpM1D5nHWzPetteZb3wg2eB2YqYm4zSadsMtoboiNBH/3TE0awx6j+MRoxoTg/IYRvP19TQrJS0bzhdHGSyKFkLTtjSKwMjyiEz43ynhtP6bdjBCWyFobAf7eT7VhNF/q1FRbjYjmUohlCVPwnB+6FUxMTJipqSmUUhhjEGKd3bMT4ks/Y6oLBK2Yth8hHYtCJXOix7Nf7xLMzc0xOzvLzp078TyPNE3viW3QJPXzhNWbxFFKHCmMhoLn/FHodd48vGfhapdAacXQlkFK5dL6wIUm6fuTZPuvqDQhaMUYYyiVyuQr6rXDexYuAdi3tSv1ZJNs/R/CaszzT+1na88uXFnCEnJVgivBNN8uTJKmHQI/ptOOcXNZzMz9mOqFs90OHpipWcYwlo5P4ebnuOkrvr5wgrH+h3im7y36MzuwRXYZeKha/OhP0EkadFoxQSdGSotedR/+XwMc2XvKdNUFOFqZx6LKZWIiwjgkikNmLp/hm8sH+K1zjFTHXfBYdTi+eJArzXM0GxFxoBDCopLvo/fqEwi1XPkWkGqjFo2TgB1jOYZUKZTS/D1/ncmLh7jon0IbRWoiTi59ymzzJEEQE3cStNZsGxqlfPE57MBbOR8fP3hDGalOO9fq2DlBvmZw8xa2IxACGn6TydlD/O6f5OzSV/zif0cYhLQaEXGkKBbz7Ov/AOlXV1cxgBJRI3fuSTrpTawt18kWIZN1CFuaONI0w0WOXfsI43YIggh/KUSlhqxrMz74AkOZcWBm9QkH+Gw8NDLuITi+m0yzhluSyJzBLcpblUhFxywSRAEtPwQjsKVN30CNh0uvYuOubSHLtN3J0TO1j0pmBNuFbFWRK0gyPRZpktL2I5JQkclKakNlnh54g6ocvevUr/Ai2a7wineEkcJupA3S1Wg0nVZM2E6wbEF5U5G9Q++wI7sfR7h3N8HVNstykBfzH+KJEZwiWD0aIwxCgJ0R1Mu7GXOeJSuK93bZtQIle4D9pUNU5DC5jEsu55AvZakM5NicGyEj8uuz8bUCQgj67QfY671P3vEoeC69gy695U1U7NG7XV0pUwBjDJa1/JJlWWxzHuflzQe5FJ/GsgUVuZ2t8lEkTvfc0aNHb72flBhjVicQQqCUuvM3/M+WDVguWBrMVdDXEGZlBVEUrVCU9d9s5+fnaTQa2PZyPxEIhJaI1EEoZwX4ncynp6fXrmB4eJjR0VFarRbNZnP9P9rt9gohqNVq1Ov1ZbF/AZGev3hLJ2/zAAAAAElFTkSuQmCC)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\20.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Tuberculostatics, antileprotics <a name='19:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
<img src="./Pharmacology/pasted_image.png">
</p>
<h1>I.Overview</h1>

<p>
→ slender,rod-shaped bacteria<br>
<ul style='padding-left: 30pt'>
<li>lipid-rich cell walls
<ul>
<li>which cannot easily decolorized by treatment with acidified organic solvents</li>
</ul>
</li>
<li>so called "acid-fast"</li>
</ul>
→ most widely ecountered mycobacterial cause — turbelusosis<br>
<div style='padding-left: 360pt'>
— leprosy<br>
— other tuberculosis-like human infenction
</div>
→ are intracellur and generally result in the formation of slow-growing granulomatus lesions.<br>
<ul style='padding-left: 30pt'>
<li>which is responsible for tissue destruction</li>
</ul>
</p>

<h1>II.Chemotherapy for tuberculosis</h1>

<p>
→ Mycobacterium tuberculosis<br>
<ul style='padding-left: 30pt'>
<li>infecntions in the lung , genitourinary tract , skeleton , meninges</li>
<li>grows slowly [6 months - 2 years]</li>
</ul>
→ resistance readily emerge [particulary to patients who have had prior therapy]
</p>

<h1>II.A.Strategies for adressing drug resistance</h1>

<p>
→ multidrug therapy is emloyed<br>
<ul style='padding-left: 30pt'>
<li>delay or prevent mergence of resistant straints
<ul>
<li><i>Isoniazid , rifampin ( rifabutin rifafpentine) , ethambutol , pyrazinamide → "first-line" drugs</i></li>
</ul></li>
</ul>
→ therearefore treatment include<br>
<ul style='padding-left: 30pt'>
<li>minimum of two drugs [preferably both being bactericidical]</li>
</ul>
</p>

<p>
[e.g. // short course chemotherapy for tuberculosis includes [isoniazid,rifampin,ethambutol,prazinamide for 2 months<br>
and then isoniazid , rifampin for the next 4 moths.
</p>

<p>
→ drugs added usually  include<br>
<ul style='padding-left: 30pt'>
<li>aminoglycosides (<i>streptimycin,kanamycin,amikacin) or capreomycin(injection)</i></li>
<li>fluoroquinole</li>
</ul>
<ul>
<li>and perhaps a "second-line" antituberculosis agents such as 
<ul>
<li><i>cycloserine, ethionamide , p-aminosalicylic acid</i></li>
</ul></li>
</ul>
</p>

<h1>II.B.ISONIAZID [INH]</h1>

<p>
→ hydrazide of isonicotinic acid is a synthetic analogue of pyridoxine<br>
<ul style='padding-left: 30pt'>
<li>the most potent of the antitubercular drugs</li>
<li>never given as a single agent in the treatment</li>
</ul>
</p>

<p>
1.MECHANISM OF ACTION<br>
→ pro-drug<br>
<ul style='padding-left: 30pt'>
<li>activated by a mycobacterial catalase-peroxidase (KatG)</li>
<li>implicate mycolic acid production by catazyling enzymes invlovled in this process</li>
</ul>
[mycolic acid is a unique class of very long ,β-hydroxylated fatty acid found in mycobacterial cell walls.<br>
↓ mycolic acid synthesis → loss of acid-fastness after exposure to isoniazide.]<br>
→ target enzymes are<br>
<ul style='padding-left: 30pt'>
<li>enoyl acyl carrier protein reductase (InhA)</li>
<li>β-ketoacyl-ACP synthase (KasA)</li>
<li>covalently binds to and inhibit threse enzymes
<ul>
<li>which are essential for the synthesis of mycolic acid</li>
</ul></li>
</ul>
2,ANTIBACTERIAL SPECTRUM<br>
→ for bacilli in the stationary phase → bacteriostatic<br>
→ rapidly dividing organism → bactericidal<br>
→ effective against intracellular bacteria <br>
→ specific treatment of M.turbeculosis [M.kansassi]<br>
3.RESISTANCE<br>
→ several different chromosomal mutations<br>
<ul style='padding-left: 30pt'>
<li>mutation or delation of KatG[incapable of prodrug activation]</li>
</ul>
→ cross-resistance does not occur between isonazid and other antituberculosis drugs.<br>
4.PHARMACOKINETICS<br>
→ ORALLY readily absorbed.<br>
<ul style='padding-left: 30pt'>
<li>it is impaired with food [especially with carbohydrates] , aluminum-containig antacids</li>
</ul>
→ diffuse into all body fluids<br>
→ penetrates host cells and is effective against baciili growing intracellular<br>
→ drug is undergoes N-acetylation and hydrolysis → inactive products<br>
→ excretion is through glomerrual filtration<br>
5.ADVERSE EFFECT<br>
→fairly low<br>
<ul style='padding-left: 30pt'>
<li>hypersensitivity </li>
</ul>
→ peripheral neuritis <br>
→ hepatitis and idiosyncratic hepatotoxicity <br>
→ also inhibits metabolism of phenytoin.<br>
→ mental abnormalities, convulsions, seizures ,optic neuritis 
</p>

<h1>II.C. RIFAMYCINS : Rifafmpin , Rifabutin , Rifapentine</h1>

<p>
→ <i>Rifampin , rifabutin , rifapentine</i><br>
→ group of structually similar macrocyclic antibiotics	<br>
<ul style='padding-left: 30pt'>
<li>first-line drugs for tuberculosis</li>
<li>must always used with conjuction with at least one other antiturbeculosis.</li>
</ul>
</p>

<h1>II.1.RIFAMPIN</h1>

<p>
→ derived from the soil mold Streptomyces<br>
→ broader antimicrobial activity than isoniazid<br>
→ rapidly emerge during therapy<br>
<ul style='padding-left: 30pt'>
<li>never given as a single agent in the treatment of the active tuberculosis.</li>
</ul>
A.MECHANISM OF ACTION:<br>
→ blocks trascription by interacting with the β-subunit of bacterial <br>
<ul style='padding-left: 30pt'>
<li>DNA-dependent RNA polymerase[drug is specific for prokaryotes]</li>
</ul>
→ inhibit mRNA synthesis by suppressing the initiation step.<br>
B.ANTIMICROBIAL SPECTRUM<br>
→ bactericidal for both<br>
<ul style='padding-left: 30pt'>
<li>intra/extre cellular mycobacteria
<ul>
<li>inluding M.tuberculosis and atypical mycobacteria such as M.kansassi</li>
</ul>
</li>
<li>effective against G+ and G-
<ul>
<li>prophylactically for individual exposed to meningitis by [menigococci or Haemophilus influenzae]</li>
</ul></li>
</ul>
→ is the most active 	ANTI-LEPROSY drug present<br>
<ul style='padding-left: 30pt'>
<li>usually given in combination with other drugs</li>
</ul>
</p>

<h1>II.2.RIFABUTIN</h1>

<p>
→ analog of <i>rifampin</i><br>
<ul style='padding-left: 30pt'>
<li>has some activity Mycobacterium avium-intrecellulare complex</li>
<li>but less active against tuberculosis</li>
</ul>
C.RESISTANCE<br>
→ by mutation in the affinity of the bacterial DNA-dependednt RNA polymerase for the drug<br>
<ul style='padding-left: 30pt'>
<li>or by decreased permability.</li>
</ul>
D.PHARMACOKINETICS<br>
→ absorption <br>
<ul style='padding-left: 30pt'>
<li>is adequate after oral admin.</li>
</ul>
→ distribution <br>
<ul style='padding-left: 30pt'>
<li>to all body fluids and organs</li>
</ul>
→ adaqueate levels attained<br>
<ul style='padding-left: 30pt'>
<li>CFS [even in the absence of inflammation]</li>
</ul>
→drug is taken up<br>
<ul style='padding-left: 30pt'>
<li>by the liver and udergoes enterohepatic cycling
<ul>
<li>can induce the hepatic mixed-function oxidases. → shortened half-life &amp; numerous drug interaction</li>
</ul></li>
</ul>
→ elimination  of metabolites<br>
<ul style='padding-left: 30pt'>
<li>bile into the feces[orange-red colour] or </li>
<li>the urine</li>
</ul>
E.ADVERSE EFFECTS<br>
→ generally well tolerated<br>
→ nausea , vomiting and rash.<br>
→ dose intermittently or <br>
<ul style='padding-left: 30pt'>
<li>in daily dose of 1.2 grams or greater [flu-like syndrome]</li>
</ul>
F.DRUG INTERACTION<br>
→ can induce a number of cytochrome p450 enzymes<br>
<ul style='padding-left: 30pt'>
<li>↓ half-lives of other drugs admin. and metabolized by the system</li>
</ul>
</p>

<h1>II.3.RIFAPENTINE</h1>

<p>
→ activity compared to that of rifampin<br>
<ul style='padding-left: 30pt'>
<li>but has longer half-life than rifampin/rifabutin	</li>
<li>which permits weekly dosing</li>
</ul>
→ intensive phase (initial 2 months)<br>
<ul style='padding-left: 30pt'>
<li>short-course therapy for tuberculosis [twich weekly]</li>
</ul>
→ subsequent phase<br>
<ul style='padding-left: 30pt'>
<li>dose once per week for 4 months.</li>
</ul>
→ to avoid resistance<br>
<ul style='padding-left: 30pt'>
<li>shoud not used alone</li>
</ul>
</p>

<h1>II.D.PYRAZINAMIDE</h1>

<p>
→ synthetic orally <br>
→ effective bactericidal[to actively dividign organism] → antituberculosis agents<br>
<ul style='padding-left: 30pt'>
<li>used in combination with <i>isonazid,rifampin,ethambutol</i></li>
</ul>
→ moa is uknown<br>
→ must be enzymataically hydrolyzed to <br>
<ul style='padding-left: 30pt'>
<li>pyrazinoic acid [the active form of the drug]</li>
</ul>
→ active against <br>
<ul style='padding-left: 30pt'>
<li>tubercle bacilli in the acidic enviroment of lysosomes and macrophages</li>
</ul>
→ distributed throught the body<br>
<ul style='padding-left: 30pt'>
<li>penatrating CFS</li>
</ul>
→extensive metabolism<br>
<ul style='padding-left: 30pt'>
<li>5% of patients taking <i> isoniazid,rifampin and pyrazinamide</i>
<ul>
<li>liver dysfunction</li>
</ul></li>
</ul>
→ Urate retention may occur
</p>

<h1>II.E.ETHAMBUTOL</h1>

<p>
→ bacteriostatic<br>
<ul style='padding-left: 30pt'>
<li>M.tuberculosis , M.kanasassi</li>
</ul>
→ inhibits <br>
<ul style='padding-left: 30pt'>
<li><i>arabionosyl tranferase</i>
<ul>
<li>an enyzme that is important for the synthesis of the mycobacterial arabinogalactan cell wall</li>
</ul></li>
</ul>
→ can be used in combination <br>
<ul style='padding-left: 30pt'>
<li>pyrazinamide , isoniazid , rafampin to treat tuberculosis.</li>
</ul>
→ well distributed throughout the body<br>
→ penetration on the CNS is therapeutically adequate.<br>
→ excrected by <br>
<ul style='padding-left: 30pt'>
<li>glomelurar filatration </li>
<li>tubular secretion</li>
</ul>
→ optic neuritis <br>
<ul style='padding-left: 30pt'>
<li>diminished visual activity [ red and green discrimination]</li>
</ul>
→ discontinuation of the drug results<br>
<ul style='padding-left: 30pt'>
<li>reversal of the optic syndromes.</li>
</ul>
</p>

<h1>II.F.Alternate Second-line drugs</h1>

<p>
→ <i>streptomycin , para-aminosalicylic acid , ethionamide , cycloserine , capreomycin , fluoroquinolones and macrolides.</i><br>
→ considered to be 2n line of therapy either because<br>
<ul style='padding-left: 30pt'>
<li>are no more effective than the first-line agents</li>
<li>toxicities are often more serious</li>
<li>active against atypical straings of mycobacteria</li>
</ul>
</p>

<h1>II.F.1.STREPTOMYCIN</h1>

<p>
→ 1st antibiotic effective in the treatment of "tuberculosis"<br>
→ action is directed agaist extracellular organism<br>
→ in case of resistance<br>
<ul style='padding-left: 30pt'>
<li>kanamycin or amikacin can be used</li>
</ul>
</p>

<h1>II.F.2.CAPREOMYCIN</h1>

<p>
→ peptide that inhibits protein synthesis<br>
→ admin. parentally <br>
→ primarly reserved for the treatment of multidrug-resistant tuberculosis.
</p>

<h1>II.F.3.CYCLOSERINE</h1>

<p>
→ effective tuberculostatic agent<br>
<ul style='padding-left: 30pt'>
<li>antagonize the steps in bacerial cell wall synthesis involing D-alanine.</li>
</ul>
→ distributed well throughout body fluids [including CFS]<br>
→ metabolized and both parent+metabolite are excrected in the urine<br>
→ accumulation occurs <br>
<ul style='padding-left: 30pt'>
<li>renal insufficiency</li>
</ul>
→ adr<br>
<ul style='padding-left: 30pt'>
<li>epilecptic seizuresa activity </li>
<li>peripheral neuropathies</li>
</ul>
</p>

<h1>II.F.4.ETHIONAMIDE</h1>

<p>
→ structual analog of isoniazid<br>
<ul style='padding-left: 30pt'>
<li>can inhibit acetylation of isoniazid
<ul>
<li>effective after oral administration </li>
</ul>
</li>
<li>widely distributed throughout the body including CFS</li>
</ul>
→ metabolism is extensive<br>
<ul style='padding-left: 30pt'>
<li>urine [main route]</li>
</ul>
→ gastric irritation,hepatotocicity,peripheral neuropathies,optic neuritis.<br>
[supplementation with vitamain B6(pyridoxine) may lessen the severity of the neurologic side effects.
</p>

<h1>II.F.5.FLUOROQUINOLONES</h1>

<p>
→ <i>ciprofloxacin , azithromycin </i><br>
<ul style='padding-left: 30pt'>
<li>part of therapy regime that incldes
<ul>
<li>ethambutol and rifabutin </li>
</ul>
</li>
<li>used for the treatment of infenciton by M.avium-intracellulare complex.</li>
</ul>
→ prefered for HIV-infected patients.<br>
→ interfere with the metabolism of antiretrovial drugs.
</p>

<h2>III.CHEMOTHERAPY FOR LEPROSY (Hansen's diseae)</h2>

<p>
→ 70% of all cases in the world are located in India<br>
→ bacilli from skin lesions or nasal discharges of infected patients enters susceptible individuals via <br>
<ul style='padding-left: 30pt'>
<li>abraded skin or the repsiratory tract </li>
</ul>
→ WHO recommends the triple-drug therapy.<br>
<ul style='padding-left: 30pt'>
<li><i>dapsone,clofazimine rifampin </i>for 6to24months.</li>
</ul>
</p>

<h1>III.A.Dapsone</h1>

<p>
→ structually related to the sulfonamides<br>
→ inhibits folate synthesis <br>
<ul style='padding-left: 30pt'>
<li>dihydropteroate synthase inhibtion</li>
</ul>
→ bacteriostatic<br>
→ well absorbed from the GIT<br>
<ul>
<li>distributed thought the body with high levels on the skin</li>
</ul>
→ enteropathic circulation and undergoes hepatic aceylation<br>
→ eliminated in urine<br>
→ hemolysis<br>
<ul style='padding-left: 30pt'>
<li>especially in patients with glucose-6-phosphate deydrogensae deifcieny</li>
</ul>
→ peripheral neuropathy.
</p>

<h1>III.B.CLOFAZIMINE</h1>

<p>
→ phenazine dye that bind to DNA and prevents it from serving as a template for future DNA replicaton.<br>
<ul style='padding-left: 30pt'>
<li>redox properties → generation of cytotoxic oxygen radicals(also toxic to bacteria)</li>
</ul>
→ bactericidal  to <br>
<ul style='padding-left: 30pt'>
<li>M.leprae</li>
<li>some activity against M.avium-intracellular complex</li>
</ul>
→ oral absorption <br>
<ul style='padding-left: 30pt'>
<li>accumulates in tissues</li>
<li>allowing intermittent therapy</li>
<li>does not enter CNS</li>
</ul>
→ patients may develop<br>
<ul style='padding-left: 30pt'>
<li>red-brown discoloration of the skin.</li>
</ul>
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>73.7kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
